Primary Peptides Inc is a clinical-stage biotech company based in Vancouver, Canada. We are developing novel peptide therapeutics using two platform technologies: 1) peptide array for identifying, targeting, and disrupting specific protein-protein interactions; 2) peptide-mediated protein knockdown technology that can replace antisense and siRNA technology platforms in many indications with greater specificity and greater temporal precision. We have signed 4 pharma partnerships so far. Our 1st lead compound has finished a phase 1 clinical trial in healthy volunteers in 2020. The 2nd and 3rd lead compounds are in IND-enabling studies. Several other compounds in the pipeline.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
British Columbia
Company HQ Country:
Canada
Year Founded:
2013
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
stroke, heart attack, Parkinson's disease, cancer, neurodegeneration
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
6
Speaker
